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ABSTRACT  the display of peptides and proteins on the surface of filamentous bacteriophage is a powerful methodology for selection of peptides and protein do-
mains, including antibodies. An advantage of this methodology is the direct physical link between the phenotype and the genotype, as an analyzed polypeptide and 
its encoding DnA fragment exist in one phage particle. Development of phage display antibody libraries provides repertoires of phage particles exposing antibody 
fragments of great diversity. the biopanning procedure facilitates selection of antibodies with high affinity and specificity for almost any target. this review is an 
introduction to phage display methodology. It presents recombinant antibodies display in more details:, construction of phage libraries of antibody fragments and 
different strategies for the biopanning procedure.
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INTRODuCTION
In the mid-eighties, a novel molecular-biological methodology 
which revolutionized the engineering of peptides and proteins 
was developed. this approach is known as phage display. It is 
based on the experiments of George Smith performed in the 
mid-80s [1]. Initially, Smith demonstrated that an exogenous 
protein can be expressed on the surface of the filamentous 
M13 phage. this was achieved by inserting the gene that en-
coded a part of the ecorI endonuclease into the OrF of the 
phage’s minor capsid protein pIII. using polyclonal antibodies 
specific to the ecorI endonuclease, Smith demonstrated the 
ability of phages carrying the chimeric ecorI–pIII protein to 
specifically bind the appropriate antibodies. Furthermore, it 
was shown that phages with this insertion could be selected 
from a mixture containing wild-type phages by affine enrich-
ment using polyclonal antibodies against the ecorI endonu-
clease.
these experiments led to two important conclusions: first, 
using DnA-recombination methods, it is possible to create 
phage populations of different representativity (106 – 1011 
variants), wherein each individual phage displays a random 
peptide on its surface. Such populations were named “combi-
natorial phage libraries.” Second, physical link between the 
analyzed polypeptide and the gene encoding it in the same 
phage particle provides the opportunity for easy selection of 
the needed variants and their identification. 
G. Smith termed the result of expression of exogenous 
oligo- and polypeptides on the surface of viable filamentous 
phages “phage display.” Furthermore, a method of affinity 
enreichment named “biopanning” was developed. According 
to this method, phages bearing inserted sequences with af-
finity to specific ligands can be selected from a phage library. 
the term “biopanning” was suggested in 1988 [2].
the small number of pIII molecules in the phage particle 
(5 copies) limits the use of phage displays in selection of syn-
thetic immunogens. Still, attempts to obtain phages exposiung 
exogenous peptides as portions of the pVIII protein, which is 
present in 3,000 copies in each virion, were unsuccessful. Only 
the studies performed by russian researchers managed to 
map a site on the n-terminus of pVIII that was exposed on 
the surface and was immunogenic but did not lead to signifi-
cant disturbance of the filamentous phages’ morphogenesis 
[3, 4].  
In the 1990s, phage display was used in order to expose the 
antigen binding fragments of immunoglobulins on the surface 
of the fd phage [5]. this led to a novel combinatorial approach 
in the development of recombinant antibodies, which was an 
alternative to the traditional hybridoma technology. Accord-
ing to this approach, the phage system allows to replace all 
the stages after immunization of animals and spleen removal 
by simple manipulations with DnA and bacteria. In addition, 
it reduces the time needed to obtain stable antibody-produc-
ing clones from months to weeks. It also reduces the cost of 
the whole procedure. 
Years of using phage display have led to several important 
areas of application:
Phage Display of Peptides 
- the study of receptors and mapping of antibody binding sites 
- the creation of immunogens and nanovaccines 
- Mapping of substrate binding sites for proteases and kinasesreVIeWS
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Phage Display of Proteins and Protein domains 
- Selection of antibodies with specific properties
- Study of protein-ligand interactions
- Screening of expressed cDnA fragments
- Directed evolution of proteins 
this review decribes the main principles and methods 
applied in phage display technology based on filamentous 
phages. Special attention is paid to the display of recombinant 
antibodies.
MORPHOLOGy AND LIFE CyCLE OF 
FILAMENTOuS BACTERIOPHAGES 
Phage display methodology and its success are defined by the 
features of filamentous phages. currently, several filamen-
tous bacteriophages are known to infect gram-negative bac-
teria. the best characterized are the М13, f1, and fd phages, 
which infect Escherichia coli strains that carry an F-conju-
gative plasmid. the genomes of these phages have been se-
quenced and are 98 % homologous [6, 7]. Based on this homol-
ogy and also on the dependence of infection on the presence 
of an F-plasmid, these phages are all termed Ff-phages.
An Ff-phage genome is a single-stranded covalently closed 
DnA, 6407(8) nucleotides in length, which encodes 11 genes. 
these genes are grouped in the genome according to their 
functions: the first group (genes II, V, X) encodes proteins 
needed for the replication of the phage DnA; the second 
group (genes III, VI, VII, VIII, IX) encodes surface-envelope 
proteins; and the third group (genes I, IV, XI) encodes pro-
teins necessary for virion assembly. In addition, the phage 
DnA carries an intergenic region which contains an ori (origin 
of replication) site for synthesizing (+) and (-) DnA chains, as 
well as a site called the “packaging signal,” which initiates 
virion assembly.
Ff-phage DnA is enclosed in a flexible cylinder comprised 
of approximately 2,700 molecules of pVIII (Fig. 1). One end of 
the Ff-phage carries 5 copies of the minor surface proteins 
pIII and pVI; the other, pVII and pIX. 
Infection of E.coli cells by the Ff-phage starts with a 
specific interaction between pIII and the top of the F-pilus, 
which is a protein tube made up of pilin subunits. retraction 
of the pilus, caused by de-polymerization of pilin subunits, 
pulls the bacteriophage towards the cell [8]. After the phage 
DnA penetrates into the cytoplasm, it is turned into a repli-
cative plasmid-like molecule (rF molecule) by the E.coli rep-
lication enzymes. this molecule then acts as a template for 
transcription and translation of phage proteins. 
Phage protein production is enhanced as the number of 
rF-molecules increases, and after reaching a certain concen-
tration of the pV protein, the newly synthesized ssDnA forms 
a DnA-рV complex, which is used in bacteriophage assem-
bly. Assembly takes place in an area of tight contact between 
the cell wall and the cellular membrane and continues until 
the end of the phage DnA is freed and the phage leaves the 
cell. Assembly of the virions does not lead to cell lysis, and 
the infected cells continue to divide, although slower than 
uninfected cells [9].
FILAMENTOuS PHAGE-BASED VECTOR SySTEMS
A number of novel vector molecules have been construct-
ed on the base of filamentous phage DnA. these so-called 
“phagemids” combine the characteristics of plasmids and 
phages [10]. Phagemids contain a replication origin and the 
packaging signal of the Ff-phage, as well as a replication 
origin for the chosen plasmid, gene III, a polylinker, and an 
antibiotic-resistance gene [11].
Several phage display systems were developed on the base 
of five capsid proteins [12], but systems based on the minor 
envelope protein pIII or the major envelope protein pVIII are 
mainly used (Fig. 2). these vector systems are termed system 
3 and 8, respectively [10]. 
Depending on the size of the exogenous insert, the enve-
lope protein of the phage may lose its normal virion assembly 
or cell infection, both of which lead to decreased viability of 
the phage. In order to restore infectivity of phages with in-
serts, specialized vector systems were developed using intro-
duction of an additional gene encoding wild-type pIII or pVIII 
protein. the vector systems, termed 33 or 88, carry both the 
wild-type phage gene and the recombinant gene. the vector 
systems referred to as 3+3 and 8+8 have the recombinant 
gene on a phagemid, while the additional wild-type gene is 
introduced into the E.сoli cells via a “helper” phage. In both 
cases, the replicated phages carry both normal and hybrid 
proteins and can replicate, despite the presence of exogenous 
inserts. 
the 8+8 vector system exhibits multivalence: both wild-
type and recombinant pVIII proteins are exposed on the sur-
face of the phage particle, but since pVIII is a major envelope 
protein, only several hundred exogenous fragments can be 
exposed. Such a high valence is useful when low-affinity lig-
ands need to be selected. 
On the other hand, the main characteristic of the 3+3 
vector system is its virtual monovalence: both recombinant 
and wild-type pIII proteins are exposed on the surface of the 
phage particle, and the number of recombinant protein cop-
ies varies from 0 to 5 for each single virion. notably, only 10 
% of the phages carry even one copy of the chimeric protein, 
and the percentage of phages carrying 2 or more molecules 
pIII pVI pVIII phage  
scDNA
pVII pIX
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Fig. 1. A schematic representation of a filamentous phage: (a) wild-type 
filamentous phage; (b) filamentous phage-based phage antibody22 | ActA nAturAe |  № 3 2009
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of recombinant pIII is considerably smaller. About 90 % of 
the phages carry no chimeric protein [13]. this low valence 
leads to limited avidity, which in turn allows the selection of 
high-affinity molecules, and the 3+3 system is mostly used 
for selection of antibody fragments.
MAIN STEPS OF A PHAGE DISPLAy PROTOCOL
In order to select for target antibodies with the desired char-
acteristics, two important steps are required: first, an ade-
quate phage antibody library should be used; and second, the 
right biopanning strategy should be chosen. 
A combinatorial phage library of antibodies is a phage 
population in which each individual phage exposes a unique 
antigen-binding antibody domain on its surface as a part of 
a chimeric рIII protein. this antibody domain is most often 
a single chain-variable fragment (scFv) or Fab-fragment 
(Fig. 3). the structural and functional traits of these antibody 
fragments are reviewed in [14]. the creation of such a library 
involves the cloning of Pcr-amplified DnA fragments en-
coding Fab or scFv from different sources into the OrF of the 
рIII protein (Fig. 4). this yields a repertoire of phagemids, 
and each phagemid includes a DnA fragment encoding an 
individual antigen binding domain. transfection of E.coli cells 
with this phagemid repertoire provides a library of phages, 
and each phage exposes an individual combination of variable 
heavy- and light-chain domains on its surface. DnA ligation 
and bacterial transformation are the key steps, since they 
determine the size of the library [15].
Such libraries are characterized by the affinity level of the 
obtained antibodies, as well as the size of the library and its 
functional size. the affinity of the selected antibodies is pri-
marily determined by the size of the library that is limited 
by the efficiency of E.coli transformation. the size of the li-
brary is the number of clones growing after transformation 
of E.coli with the whole phagemid population. A much more 
important factor is the functional size of the library, which is 
the number of clones that carry correctly assembled genes 
without deletions, frame-shifts, or improper stop-codons. the 
functional size of the library is always smaller than the initial 
size, but it is the key parameter that determines the proper-
ties of the antibodies to be selected [16].
Selection of the target antibodies requires a biopanning 
procedure, an affine enrichment of the library by antibodies 
specific to the desired antigen (Fig. 5). this involves the incu-
bation of an immobilized antigen with the phage library. the 
unbound phage antibodies are removed, and the bound ones 
are eluted and used for infecting E.coli, where they replicate. 
these phages are then extracted and used for the next round 
of biopanning. Ideally, one round of biopanning should be 
enough, but nonspecific binding limits the enrichment dur-
ing each single round; so, several rounds of selection are usu-
ally required. then, individual antibodies directed against a 
specific antigen are selected from the enriched library.
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Fig. 3. Natural immunoglobulin G molecule and the antigen-binding frag-
ments of the immunoglobulinreVIeWS
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TyPES OF PHAGE ANTIBODy LIBRARIES 
there are two types of in vitro-made phage antibody librar-
ies: the so-called “natural” and “synthetic” libraries, which 
are further subdivided according to the used gene reper-
toire. 
currently, a number of phage display antibody libraries 
have been fully or partially obtained from natural sources; 
thus mrnA was extracted from peripheral lymphocytes, 
bone marrow or the spleen [17, 18]. Libraries of human an-
tibodies are of special interest, since the selected antibodies 
can be used for the development of therapeutics. Since most 
of the families encoding human V-genes are rarely used in 
the immune response, only the often-occurring gene families 
are usually used for library construction: VH1 – VH3 (from the 
heavy-chain gene family) and VK1 – VK4, and also Vλ1 – Vλ3 
(from the light-chain gene family). Both random recombina-
tion of the light- and heavy-antibody chains and the variabil-
ity of the hyper-variable regions (complementarity determin-
ing region – cDr) of the VH and VL chains play an important 
role in the variability of the library. .
natural antibody libraries are divided into “immune” and 
“naïve” libraries. Immune libraries based on peripheral lym-
phocytes extracted from humans immunized by a certain an-
tigen are valuable for medical research, since they provide 
increasing probability of selecting antibodies that could be 
used for therapy [19]. 
“naïve” libraries based on lymphocyte mrnA extracted 
from unimmunized healthy people are used for obtaining 
antibodies directed against a wide multitude of antigens, 
including autoantigens [20]. these “naïve” libraries mostly 
represent the germline diversity of antibodies. 
Synthetic libraries were introduced in order to increase 
the variety and size of the library and to enhance the anti-
body’s characteristics. Synthetic phage antibody libraries are 
divided into two groups: 
1) Synthetic libraries based on a single-core V-gene; 
2) Synthetic libraries based on a multiple-core V-genes.
Libraries of the first type are based on a single gene, which 
is then mutagenized in all the cDrs or just the cDrs in the 
VH-domains. In this case, library diversity is limited by the 
degeneracy of the synthetic DnA which is used to change the 
sequence of the cDr-loops. 
Synthetic libraries based on a single-core sequence present 
several advantages. they are easier to construct, and the ob-
tained antibodies can be analyzed in less time. But the issue 
remains as to whether a single core sequence allows the cor-
rect folding of various antigen-binding cDrs providing a 
wide range of high-affinity antibodies. 
Synthetic libraries of the second type are based on tens of 
genes, which are mutated in all the cDrs or in the cDrs in 
the variable domains of the heavy chains. 
Different types of genes (Fab and scFv) can be used for 
creating both natural and synthetic phage libraries. thus, 
combinatorial phage libraries of Fab- or scFv- antibody frag-
ments can be obtained. 
After Мaccafferty and his collaborators demonstrated the 
possibility of creating a scFv library on the surface of a fila-
mentous phage [5] in 1990, much research has been aimed at 
developing such libraries and studying the selected recombi-
nant antibodies. In order to create a scFv library, populations 
of VH- and VL-genes are combined into a single DnA sequence 
by using an oligonucleotide encoding a flexible hydrophilic 
peptide (Fig. 3). this linker consists of glycine and serine 
residues (Gly4 Ser)3 which make it flexible and resistant to 
proteases. then, the obtained scFv-genes are cloned into an 
appropriate vector (pHen1, pHen2, pSeX, etc.), which ex-
presses the scFv-antibodies as part of the chimeric pIII pro-
tein. the heavy chain is most often immediately downstream 
from the leading sequence, while the light chain is fused to 
the n-terminal pIII sequence. the peptide linker facilitates 
the association between the VH- and VL domains necessary 
for forming the antigen binding surface, so disulfide bonds 
between the chains are not needed. 
For further purification and characterization, it is con-
venient to produce the scFvs as secreted proteins. If pHen 
or pSeX vectors are used, an amber stop codon inserted be-
tween the 3’-terminus of the scFv gene and the 5’-terminus 
of the pIII gene provides production of scFv. in nonsuppressor 
E. coli strains  transformed by the phagemids [21].
Fab-fragments are heterodimers consisting of a light im-
munoglobulin chain (VL–cL) combined with a variable domain 
and the first constant domain of a heavy chain (VH-cH1). the 
chains interact after both have been synthesized, and this in-
teraction stabilizes the formation of the antigen-binding site 
(Fig. 3). creating Fab-libraries involves cloning a light chain 
and an Fd-domain (VH + cH1) into the appropriate vector. the 
RNA
cDNA
PCR of the VH- 
and VL-genes
Insertion into  
the phagemid  
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Transformation  
into E. coli
Amplification of phage particles
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pIII
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Fig. 4. A schematic representation of the construction of an antibody 
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gene encoding the Fd-domain is combined with the region 
encoding the c-terminus of the pIII phage protein. thus, the 
Vl-gene and the Vh-gene, which is fused with the pIII phage 
protein, are transcribed as a polycistronic mrnA under the 
control of the chosen E.coli promoter. the n-terminus of each 
polypeptide consists of a leading sequence, which directs it 
towards the cellular membrane where virion assembly takes 
place. 
A wider range of Fab-fragments can be obtained by trans-
forming cells with plasmid bearing VНcH1-chains and then 
transfecting the same cells with a phage population exposing 
VLcL-chains. In this case, complete chain recombination must 
be assured, so that the chains are all present in the phage par-
ticle for the following selection procedure. In order to achieve 
the recombination of the Н- and L-chains in vivo, both the 
plasmid and the phagemid contain loxP-sites for the phage 
recombinase P1, and the E.coli strain is modified to produce 
phage recombinase [22]. 
Fab-fragments are usually more stable after purification 
as compared to scFvs. they also have a longer elimination 
half-life and thus better pharmacokinetic and pharmacody-
namic qualities [14]. In addition, Fab-fragments can be turned 
into full-sized immunoglobulins relatively easily by combin-
ing the c-terminus of the cH1 domain with the Fc-fragment.
LIBRARy CONSTRuCTION
Different sources of gene repertoire are used for the con-
struction of phage display antibody libraries, depending on 
the library type. naïve and immune libraries are constructed 
using naturally reorganized genes, which encode the variable 
immunoglobulin domains of healthy donors or donors immu-
nized with a certain antigen, respectively (Fig. 4). mrnA from 
the antibody-producing lymphoid cell line is isolated for this 
purpose: peripheral blood lymphocytes are mainly used, but 
splenocytes [23, 24], tonsil cells, and В-lymphocytes from the 
bone marrow, have been used as well [25, 26]. A preliminary 
in vitro immunization of peripheral lymphocytes can also be 
used to construct an immune antibody library [27, 28].
 cDnA is then synthesized on the base of isolated mrnA, 
and both oligo-dt and statistically devised hexanucleotides 
and specific primers can be used that yield cDnA copies of 
all the possible variable domain genes [29]. Also, one or sev-
eral primers can be used to limit the range of amplified genes 
to one or several variable domain gene families or antibody 
isotypes [30]. Information from the DataBase Kabat [31] or V 
BASe can be used for primer development. the primer se-
quence usually includes restriction sites for cloning the Pcr-
products into the appropriate vectors.
Naïve library construction. Phage display library of human 
scFv was constructed by Marks and his colleagues [30]. Pe-
ripheral blood lymphocytes isolated from two volunteers 
were used as a gene source. the primers used for cDnA syn-
thesis were complementary to the conservative regions of the 
genes encoding the κ- and λ-type light chains and the IgM 
and IgG heavy chains. the cDnAs were than cloned into the 
pHen1 vector, yielding two libraries: VHμ–VL (2.9 ∙ 107 clones) 
and VHγ–VL (1.6 ∙ 108 clones) [30]. Various protein-, hapten- 
[30], and autoantigen-specific antibodies were selected from 
these libraries [30, 32], although the affinity constants of the 
selected scFv’s did not exceed 107 M-1. Still, high-affinity an-
tibodies can be extracted from relatively small-sized libraries. 
For instance, a scFv-library containing 4 ∙ 107 clones yielded 
scFvs specific to steroid hormones, and their affinity con-
stants were 107 – 108 М-1 [33]. Single-chain antibodies specific 
to the tumor necrosis factor (Ka = 107 – 108 М-1) were selected 
from a naïve library of 2 ∙ 108 of independent clones. In order 
to increase the representativity of this library, the protocol 
for obtaining scFv-genes was modified. In contrast to previ-
ous work [30], in which the scFv-genes were constructed by 
3-component Pcr (VH – linker – VL), a more efficient two-
component reaction was used, involving a restriction site in 
the linker sequence [16].
Further experimental efforts were aimed at constructing 
the wider variety of antibody fragments, since antibodies 
with nanomolar affinity to any antigen can be selected from 
a large repertoire (1010–1011). Such a library (1.4 ∙ 1010 clones) 
was developed on the base of the genetic material extracted 
from the lymphoid cells (peripheral blood lymphocytes, tonsil 
cells, and bone marrow B-lymphocytes) of 43 unimmunized 
donors [25]. VH- and VL-gene repertoires were preliminar-
ily cloned into pcantab 6 and pcantab 3His6 vectors, respec-
tively. the affinity of the antibodies obtained from this scFv 
library exceeded 109 M-1. It was known that antibodies with 
such affinities usually appeared after a secondary immune 
response. this library also yielded antibodies specific to cell 
surface antigens [34] and an antibody that could specifically 
bind carbohydrates [35]. Also, antibodies specific to various 
toxic agents were obtained from this library. this result dem-
onstrated an advantage for large libraries when compared to 
the hybridoma technique, because toxic agents were impos-
sible to use for immunization [10]. naïve scFv libraries were 
also used to obtain scFv specific to neurotoxins [36], to apop-
tosis proteins [37], etc. 
the creation of a large naïve library of Fab fragments in-
volved a two-step cloning strategy [24].  First, amplified VH-, 
VLκ- and VLλ-genes were cloned into vectors bearing the cH1, 
СLκ- and СLλ-genes, respectively. After that, restriction frag-
ments which were obtained from the initial VHСH1, VLκСLκ, 
and VLλСLλ gene repertoires were used instead of the usual 
Pcr products. this approach made the cloning procedure 
more effective. Similarly to the creation of scFv libraries, the 
oligonucleotides for the amplification of the variable domains 
were chosen to maximize the output of the gene repertoire. 
the resulting Fab-fragment library contained 3.7 ∙ 1010 inde-
pendent clones, and the affinity of the antibodies selected for 
a wide range of antigens varied from 2.7 ∙ 107 to 3.7 ∙ 108 М-1.
Synthetic library construction. combinatorial libraries are 
characterized not only by size, which is determined by the 
number of clones, but also by representativity, which is the 
overall number of different VH–VL combinations. One way 
to extend the representativity of a library is to increase the 
number of donors, and this way is particularly used for natu-
ral libraries. However, the antibody-encoding gene repertoire 
still does not exceed the variability of the lymphoid cell genes 
available for library construction. the potential antibody 
repertoire in the human organism is supposed to reach 1012, 
but the antibody-producing cells represent only a portion of 
that amount at a moment [37, 38]. A second way to extend the 
representativity of a library is to replace natural cDrs with 
synthetic ones. In this case, it is possible to construct a combi-reVIeWS
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natorial library including all the possible antigen-binding se-
quences of antibodies. Such phage display libraries are usual-
ly termed semi-synthetic or synthetic, depending on whether 
one or both variable domains contain synthetic cDrs. An ide-
al way to produce a repertoire that would encompass all the 
possible antibody sequences would be to chemically synthe-
size all 6 randomized cDrs and then connect them via various 
structural domains. But usually СDr3 of the heavy chain is 
randomized, since it is the most significant component of the 
antigen binding site [39]. 
the first semi-synthetic library was based on one heavy 
chain in which cDr3 was replaced with 1020 different se-
quences and one intact light chain [37]. this library contained 
5 ∙ 107 clones, and the affinity of selected antibodies varied 
from 107 to 108 М-1. 
Later, single-core semi-synthetic libraries were construct-
ed using mutagenesis to change all cDrs in the VH-domain 
[40]. the positions for mutagenesis were chosen according to 
the special variability of natural antibody sequences. these 
positions were randomized using the codons which are mostly 
found in natural antibodies that provided good solubility of 
selected antibodies.
Besides libraries based on a single-core sequence, some 
libraries based on a repertoire of VH-genes have been con-
structed [41, 42]. thus, the nissim library was based on 50 VH-
genes encoding most of the human V-segments and random 
nucleotide sequences encoding the VH cDr3. these sequences 
varied from 12 to 36 b.p.. this approach yielded 9 VH-gene 
repertoires whith different lengths of VHcDr3 and, thus, 9 
phagemid libraries. the size of the overall library was 108 in-
dependent clones, and this library yielded antibodies specific 
to a whole range of antigens [42]. 
Another commonly used library is the Griffin 1 library. 
It was constructed in a similar way to the previous library, 
based on 50 germline VH-genes. In addition, 6 VL-genes, cor-
responding to the 6 main subtypes of κ- and λ-chains, were 
used. the library contained 108 clones, and it yielded anti-
bodies specific to the soluble cD4 receptor [43], human inter-
leukin 6 [44], orthopoxviruses [45], and the ebola virus nu-
cleoprotein [46]. this library was also used to select catalytic 
antibodies [47] and other ones [48].
the affinity of the selected antibodies yielded by these 
semi-synthetic and synthetic libraries was not high due to 
several factors. It is known that VH cDr3 is highly variable in 
length in natural antibodies and can consist of up to 24 amino 
acid residues. creation of synthetic cDr3 sequences with 
varying lengths and completely random structures is inef-
ficient. Moreover, the structural conformation of antibodies 
with synthetic cDrs could be incorrect (compared to natural 
conformations) precisely at the cDr loops [49]. In order to 
avoid this difficulty, limited randomization and introduction 
of flanking structures that enclose the completely random 
amino acid sequences were used [49]. the resulting library 
contained 3.6 ∙ 108 clones, and scFv’s specific to different an-
tigens were selected from it, although the affinity of the se-
lected antibodies was still low (4 ∙ 105 - 107 М-1).
Further steps for avoiding the above-mentioned limita-
tions depend on the use of so-called “master-genes,” which 
are the genes encoding variable domains with specific frame 
regions flanking the various randomized cDrs. the HucAL 
library was constructed on the base of VH- and VL-gene fami-
lies, which are mostly used in the immune response. Hence, 7 
VH-genes and 7 VL-genes yielded a basic collection of 49 dif-
ferent scFv genes. All the genes were synthesized to avoid 
the codons for amino acid residues that promote aggregation 
[50]. this library was constructed according to the position 
of key amino acid residues in cDrs and the frame regions, 
the length of the cDrs, and the level of their variability. the 
synthesis of oligonucleotides encoding cDr3 involved the use 
of cassette trinucleotide mutagenesis, which removed the 
tAG termination codon and uncommonly used codons. this 
library contained 2 ∙ 109 clones, and antibody fragments were 
selected from this library for a wide range of antigens, includ-
ing peptides, proteins, and whole cells. the affinity constants 
were near those of a secondary immune response (109 M-1). 
3D structures have been created for all the used consensus 
structures. that has allowed further study of the source for 
the variability of natural structural motifs of human antibod-
ies, and also the correlations between antibody structure, its 
affinity, specificity, and the bound antigen class [50, 51]. 
the n-coDer™ library was constructed in a similar way 
[52]. A single master gene modified by introduction of dif-
ferent in vivo-formed cDrs have been used. Since the genes 
contained natural cDrs, an encreased amount of correctly 
assembled and functional molecules was guaranteed. More-
over, computer analysis showed that the antibodies produced 
from the coDer™ library were less immunogenic. this library 
yielded antibodies that were specific to carbohydrates and 
human autoantigens, with an affinity exceeding 109 М-1.
Construction of immune libraries.  Despite the fact that 
many universal naïve synthetic and semi-synthetic libraries 
have been constructed in recent years, it has become clear 
that the main problem is not the creation of an enormous rep-
ertoire of antibody fragments, but conservation of this rep-
ertoire for extended periods of time, and keeping it without 
failure in antibody structures. Also, the larger the library, the 
more practically difficult it is to work with it. For instance, 
amplification of a library with 1010 clones takes tens of lit-
ers of culture medium. this is one of the main reasons why 
smaller libraries containing a narrowed repertoire of antibod-
ies are preferable.
Immune libraries have two main features: they are en-
riched with antigen-specific antibodies, and the affinity of 
some of the antibodies has increased during the immune 
response. So, these libraries contain an extended amount of 
clones producing high-affinity antibodies specific to the anti-
gen used for the immunization and that appeared as a result 
of a secondary immune response. It is assumed that immune 
libraries containing 106 clones can yield some antibody frag-
ments that specifically bind the antigen used for immuniza-
tion. In comparison, naïve libraries must contain at least 108 
individual clones in order to possess the original variability of 
antibodies [53]. 
the first immune libraries were constructed against HIV 
[54], the respiratory syncytial virus [55], hepatitis B virus [56], 
herpes simplex virus, and cytomegalovirus [57, 58]. Libraries 
have also been constructed against human autoantigens [59–
61] and against antigens that cause allergic reactions [62]. 
Libraries based on the lymphocyte genetic material isolat-
ed from patients were constructed to select antibodies against 26 | ActA nAturAe |  № 3 2009
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specific tumor markers [63 – 68]. Immune libraries have also 
been made against the hepatitis A virus [19], chicken pox vi-
rus [69], orthopoxviruses [70], etc. recently, virus-neutraliz-
ing scFv fragments specific to the flu virus H5n1 [26, 71] and 
virus-neutralizing Fab-fragments specific to the rabies virus 
[72] were extracted from immune libraries. Full-size human 
antibodies against orthopoxviruses [73, 74], neutralizing an-
tibodies against hepatitis A [75], and neutralizing antibodies 
specific to the B glycoprotein of cytomegalovirus [76] have 
been made using antibody fragments isolated from immune 
libraries.   
A serious advantage of immune libraries is the possibility 
to select high-affinity antibodies, which appear after viral 
infections or cancer, and antibodies specific to autoantigens, 
which are present in patients with autoimmune diseases. 
Analysis of these antibodies can help in the identification of 
the antigen epitopes responsible for the humoral immune re-
sponse. Another advantage of immune libraries is that weakly 
immunogenic antigens can be used for antibody selection. 
AFFINITy SELECTION OF ANTIBODIES FROM LIBRARIES 
the next important step after constructing a library or choos-
ing an available one is the enrichment of the original antibody 
repertoire with the antibodies specific to a target antigen (Fig. 
5). this procedure is called “biopanning” or affinity enrich-
ment. Below, we present several biopanning strategies. 
Biopanning with immobilized antigens. traditionally, bio-
panning has been performed using an antigen absorbed on a 
plastic surface, for instance immunotubes (Maxisorb tubes; 
nalge nunc Intl., naperville, IL) or enzyme immunoassay 
plates [30, 78]. Biopanning can also be performed using af-
finity chromatography, which involves the immobilization 
of the target antigen in a column [43, 79]. the column is then 
washed to remove unspecific antibodies, and the bound spe-
cific phage antibodies are eluted from the column and ampli-
fied in E.coli cells. BIAcore chip sensors can also be used as 
an antigen-binding medium for affinity selection [80]. using 
this method for biopanning, it is important to keep the con-
formational stability of the antigen. Some phage antibodies 
selected against adsorbed antigens cannot bind the antigen 
in its native conformation. One method to avoid this problem 
is to use indirect antigen binding by incorporating antigen-
specific antibodies [81].
elution of the specifically bound antibodies is performed 
by using acid solutions, such as Hcl or a glycine buffer [78, 
82], or basic (alkaline) solutions, such as triethylamine [30]. 
It is very important to neutralize the phage antibody eluate 
right after elution, adjusting the pH to 7.2–7.4. Antibodies can 
also be eluted by cleaving a specially introduced site between 
the antibody and the pIII protein with a protease [83]. Moreo-
ver, antibodies can also be eluted by adding an excess of anti-
gen, since this antigen will compete with the immobilized one 
binding the antibodies [16, 43].
Biopanning using antigen solution. Immobilizing the antigen 
on a solid surface often causes conformational changes of the 
antigen molecules. to avoid conformational changes, a set 
of methods are used to bind antigens to antibodies in a solu-
tion. the use of tagged soluble antigens allows precise quan-
tification of the antigen concentration [84], and thus the use 
of minimal concentrations, which leads to selection of high 
affinity antibodies. After incubating the antibodies with an 
antigen conjugated with biotin, phages bound to the tagged 
antigen are collected with avidin- or streptavidin-covered 
paramagnetic beads. then, the specifically bound phages can 
be eluted from the antigen and characterized. A drawback of 
this method is the co-selection of anti-streptavidin antibodies. 
this problem can be solved by adding one more step; incuba-
tion of the antibodies with streptavidin-covered beads so as 
to remove any streptavidin-specific antibodies.
Biopanning on cells. Direct antibody selection against cell 
surface markers can be performed using either a cell monol-
ayer or a cell suspension. the unbound phage antibodies are 
removed by washing the culture dishes in the case of a mon-
olayer and by centrifugation in the case of a suspension. In 
order to optimize the selection of antigen-specific antibodies 
and minimize the selection of nonspecific antibodies, a nega-
tive selection procedure can be performed before, after or 
simultaneously with the positive selection [49]. Simultaneous 
positive and negative selection creates competitive condi-
tions: a small number of antigen-positive (target) cells and 
an excess of antigen-negative adsorbing cells, which bind the 
unspecific antibodies from the phage library.  In order to col-
lect the cells with the bound phage antibodies, fluorescently 
labeled antibodies specific to another antigen on the target 
cell surface are added to the suspension. the cells are then 
collected by a FAcS-sorter.
using a similar method, anti-rh(D) Fab-antibodies, which 
are very promising for clinical use, have been extracted from 
a Fab-fragment library [85]. Similar approaches can be used 
for identifying tumor-specific antigens and also as a highly 
productive protocol for selecting antibody fragments specific 
to conformation-dependent cell surface markers. A scFv-
library was subjected to 3 rounds of positive selection using 
human melanoma cells and negative selection using human 
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initial library with 
the antigen
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peripheral blood mononuclear cells [64]. two scFv, which 
could bind melanoma cells according to the enzyme immu-
noassay and FAcS, were selected with this procedure [64]. 
Similar selection can be performed using fragments of vari-
ous tissues.
A novel method has been developed for selecting antibod-
ies which can penetrate eukaryotic cells via receptor-depend-
ent endocytosis. In this case, selection is performed under 
conditions that stimulate active endocytosis. thus, after lysis 
of the used cells, a population of phage antibodies which are 
able to penetrate eukaryotic cells can be obtained [86, 87]. It 
is suggested that such antibodies can act as vehicles for intro-
ducing various drugs into cells. 
In vivo biopanning. this method involves a direct injection 
of the antibody repertoire into an animal’s organism. tissues 
are then removed and phage antibodies bound to tissue-spe-
cific cell markers can be extracted. A similar approach was 
used for peptide libraries [88]. In vivo biopanning has several 
advantages: first, the extracted antibodies specifically bind 
intact cell targets; second, antibodies binding nontarget cell 
surface proteins and blood plasma are immediately eliminat-
ed. Antibodies obtained via in vivo biopanning or cell biopan-
ning can be very useful for the functional analysis of newly 
discovered receptors and in the search for potential targets 
of novel drugs. 
notably, most of the existing selection procedures involve 
only one or several antigens. However, there are biopanning 
strategies that allow parallel selection for antibodies against 
a population of antigens; the so-called “2D display.” thus, it 
has been proposed to incorporate multiplex flow cytometry 
for high-output simultaneous selection of individual antibod-
ies against a wide range of antigens present on the surface of 
cells [89]. An alternative method of selection against a popula-
tion of antigens is the combinatorial selection of antigen-anti-
body pairs which are able to replicate. Such an approach was 
used for selecting a scFv phage library for antibodies specific 
to antigens from a yeast library [90].
PROBLEMS AND SuCCESSES OF DISPLAyS 
BASED ON FILAMENTOuS PHAGES 
Many researchers have faced a number of problems while 
constructing and using libraries based on filamentous phages. 
For instance, the low concentration of the original antigen-
specific lymphocytes in the population can be a problem while 
constructing immune libraries. this and similar problems can 
be avoided by preliminary enrichment of the B-lymphocyte 
population, using antigen molecules conjugated with mag-
netic beads [91, 92].
Another difficulty is selective loss of high-affinity an-
tibodies during biopanning cycles. Another problem is the 
decrease of the share of phages with full-sized inserts dur-
ing library amplification and propagation. Analysis of the 
antibody-encoding gene’s size showed that the number of 
clones with defective inserts increased after even one round 
of biopanning [16]. Phages with smaller inserts (usually with 
an absent VH region) tend to grow more quickly than phages 
with full-sized inserts, which leads to their more effective 
amplification. that is why using the appropriate biopanning 
strategy is so important. Varying the elution and screening 
conditions during selection can help to select  high-affinity 
antibodies.  
Another problem is the big difference between the the-
oretically possible and the actual variety provided by the 
phagemid population. this difference cannot be fully ex-
plained by cell transformation efficiency. It can also be caused 
by cell toxicity of the antibodies, incorrect protein folding or 
assembly, competition between the chimeric and wild-type 
рIII proteins, proteolysis of the antigen-binding site on the 
surface of the phage, and several other factors.
nevertheless, despite the existing methodological prob-
lems, phage display techniques are showing considerable 
progress. this technology is a very promising instrument 
for several reasons. Human antibody fragments selected 
from phage display libraries could be useful in the con-
struction of fully human antibodies that have lower im-
munogenicity than chimeric or humanized antibodies and 
would be more valuable for therapeutic use. Antibody frag-
ment libraries allow the rapid isolation of specific antigen-
binding domains without any of the limitations caused by 
the availability of donor lymphocytes or cell-fusion dif-
ficulties. Another advantage of phage display libraries is 
that one library can be used for multiple screening against 
different antigens. One more advantage of this technology 
is the absence of laboratory animal use, the relative sim-
plicity of the protocols, and the possibility of screening a 
large amount of candidate molecules in a short period of 
time. A very important feature is the possibility of select-
ing antibodies against a wide range of antigens, including 
toxic substances or highly dangerous viruses, which can-
not be used for immunization because of ethical reasons. 
Phage display technology has proved its effectiveness in 
the development of therapeutic antibodies. In recent years, 
more than 14 antibodies on the u.S. pharmaceutical market 
have been obtained using phage display methods [15]. All 
these facts explain the interest of large companies, such 
as Morphosys GmbH (Germany; http://www.morphosys.
com); cambridge Antibody technology (united Kingdom; 
http://www.catplc.co.uk), Dyax (uSA; http://www.dyax.
com) and others, in the development and application of an-
tibody fragment phage display libraries.   
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